Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-beta-Lactamase-1.
Loading...
Issue Date
8/14/2020
Authors
Yasmin, Mohamad
Fouts, Derrick E
Jacobs, Michael R
Haydar, Hanan
Marshall, Steven H
White, Richard
D'Souza, Roshan
Lodise, Thomas P
Rhoads, Daniel D
Hujer, Andrea M
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
In an infection with an Enterobacter sp. isolate producing Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-beta-Lactamase-1 in the United States, recognition of the molecular basis of carbapenem resistance allowed for successful treatment by combining ceftazidime-avibactam and aztreonam. Antimicrobial synergy testing and therapeutic drug monitoring assessed treatment adequacy.
Citation
Yasmin M, Fouts DE, Jacobs MR, Haydar H, Marshall SH, White R, D'Souza R, Lodise TP, Rhoads DD, Hujer AM, Rojas LJ, Hoyen C, Perez F, Edwards A, Bonomo RA. Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1. Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155. PMID: 31802119; PMCID: PMC7428388.
ACPHS Research Commons URI
Description
Grants
U19 AI110819/AI/NIAID NIH HHS/United States , R01 AI100560/AI/NIAID NIH HHS/United States , R01 AI063517/AI/NIAID NIH HHS/United States , R01 AI072219/AI/NIAID NIH HHS/United States